DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the VINEET LABORATORIES LTD (VINEETLAB) share price today?

VINEET LABORATORIES LTD (VINEETLAB) is trading at ₹36.98 on the NSE, down 2.81% on the day. Source: DocStoX.

What is the PE ratio of VINEET LABORATORIES LTD?

VINEET LABORATORIES LTD has a price-to-earnings (PE) ratio of 68.5 in the Healthcare sector.

What is the market capitalisation of VINEET LABORATORIES LTD?

VINEET LABORATORIES LTD has a market capitalisation of approximately ₹70 crore.

VINEET LABORATORIES LTD

VINEETLAB·NSE·Healthcare

₹36.98▼ -1.07 (-2.81%)

Healthcare · Pharmaceuticals

Carries meaningful debt — watch the balance sheet

Day₹36.65

₹38.65

52W₹28

₹5041%

Open

₹38.65

High

₹38.65

Low

₹36.65

Prev Close

₹38.05

Volume

1.69L

VWAP

₹38.25

Snapshot

Key fundamentals

Market Cap

₹70 Cr

P/E Ratio

68.48Expensive

P/B Ratio

4.54

EPS

₹0.54

Book Value

₹23.00

ROE

-137.85%Weak

ROCE

7.00%Weak

Dividend Yield

3.06%

Debt / Equity

2.86High

Face Value

₹10.00

52W High

₹49.99

52W Low

₹27.96

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatVery High uncertainty

Fair value estimate

₹17

▼ 54.0%downside

Trading at ₹37 — 54% above our estimate

BearFair valueBull

₹14₹17₹20

/100

Business quality — Watch the fundamentals

Growth 50Profitability 0Efficiency 0Valuation 0

Plain English

Our view

Carries meaningful debt — watch the balance sheet
High leverage — debt exceeds 1.5× equity

Risks

High leverage — debt exceeds 1.5× equity
Weak returns on equity (-138%)
Expensive — trades at 68× earnings
Fundamental red flags (Piotroski 0/9)

How we got there

Fair value methods

Residual income

Needs a return-on-equity figure

—

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹17

Analyst target

No analyst coverage

—

Blended fair value₹17

What the numbers say

Investment thesis

Bull case

No standout positives from the current metrics.

Bear case

High leverage — debt exceeds 1.5× equity
Weak returns on equity (-138%)
Expensive — trades at 68× earnings
Fundamental red flags (Piotroski 0/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

68.5Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

-137.8%Weak

Above 15% is considered healthy for Indian equities

ROCE

7.0%Weak

Above 18% means capital is working hard

Debt/Eq

2.86High

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹70 Cr

P/B

4.54

EPS

₹0.54

Div Yield

3.06%

What changed

Recent changes

Foreign investors+0.4% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 68.5×

Growth

N/A

No history

Profitability

Loss-making

-137.8% ROE

Financial health

High debt

D/E 2.86

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹64.59L Cr

Trades320

VWAP₹38.25

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

No growth history

Not enough annual history to compute CAGR.

Profile

Cons

Stock is trading at 4.35 times its book value
Company has low interest coverage ratio.
Promoter holding has decreased over last quarter: -6.48%
Promoter holding is low: 5.98%
Company has a low return on equity of -21.7% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 0.36 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

Promoter

Promoters

6.0%0.00

Public

88.7%-0.43

FII / FPI

0.4%+0.36

DII

0.0%0.00

Others

4.9%

Total shareholders

9,929-113 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter5.98%

FII0.36%

Public88.74%

Others4.92%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs